系统性硬化症广州赵岩教授_培训课件.pptVIP

6 9 12 15 18 21 24 64 66 68 70 Follow-up time (months) Adjusted FVC % predicted Placebo Cyclophosphamide n Placebo 70 65 65 55 56 51 55 n CYC 67 64 66 57 52 51 54 p-value 0.8053 0.0768 0.0400 0.3212 0.0107 0.4793 0.4223 Tashkin DP, et al. N Engl J Med 2006; 354: 2655-66. The scleroderma lung study (SLS) Thanks * Potential mechanisms of dysregulated angiogenesis in systemic sclerosis (SSc). SSc is characterized by a progressive loss of vasculature and a lack of compensatory angiogenesis.